JP2020536573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536573A5 JP2020536573A5 JP2020521372A JP2020521372A JP2020536573A5 JP 2020536573 A5 JP2020536573 A5 JP 2020536573A5 JP 2020521372 A JP2020521372 A JP 2020521372A JP 2020521372 A JP2020521372 A JP 2020521372A JP 2020536573 A5 JP2020536573 A5 JP 2020536573A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human
- amino acid
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 110
- 239000012634 fragment Substances 0.000 claims 63
- 239000000427 antigen Substances 0.000 claims 45
- 102000036639 antigens Human genes 0.000 claims 45
- 108091007433 antigens Proteins 0.000 claims 45
- 101150036449 SIRPA gene Proteins 0.000 claims 42
- 230000001588 bifunctional effect Effects 0.000 claims 35
- 239000002955 immunomodulating agent Substances 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims 20
- 230000028327 secretion Effects 0.000 claims 18
- 210000004899 c-terminal region Anatomy 0.000 claims 15
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 14
- 102000044459 human CD47 Human genes 0.000 claims 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 9
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 9
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 9
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 102000048776 human CD274 Human genes 0.000 claims 8
- 102000054189 human CD80 Human genes 0.000 claims 8
- 102000048362 human PDCD1 Human genes 0.000 claims 8
- 230000004913 activation Effects 0.000 claims 7
- 230000035755 proliferation Effects 0.000 claims 7
- 101150106931 IFNG gene Proteins 0.000 claims 6
- 108700012920 TNF Proteins 0.000 claims 6
- 210000002540 macrophage Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- 102000002627 4-1BB Ligand Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000011340 continuous therapy Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306396.7 | 2017-10-13 | ||
| EP17306396 | 2017-10-13 | ||
| PCT/EP2018/078082 WO2019073080A1 (en) | 2017-10-13 | 2018-10-15 | ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536573A JP2020536573A (ja) | 2020-12-17 |
| JP2020536573A5 true JP2020536573A5 (https=) | 2021-11-18 |
| JP7395471B2 JP7395471B2 (ja) | 2023-12-11 |
Family
ID=60143660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521372A Active JP7395471B2 (ja) | 2017-10-13 | 2018-10-15 | 改変抗ＳＩＲＰａ抗体及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11713356B2 (https=) |
| EP (1) | EP3694881A1 (https=) |
| JP (1) | JP7395471B2 (https=) |
| CN (1) | CN111511766B (https=) |
| WO (1) | WO2019073080A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| AU2019233577A1 (en) | 2018-03-13 | 2020-09-03 | Ose Immunotherapeutics | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| US20220289848A1 (en) * | 2019-05-17 | 2022-09-15 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof |
| WO2021226591A1 (en) | 2020-05-08 | 2021-11-11 | Electra Therapeutics, Inc. | Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof |
| EP4320156A1 (en) * | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| BR112023025194A2 (pt) | 2021-06-04 | 2024-02-27 | Boehringer Ingelheim Int | Anticorpos anti-sirp-alfa |
| EP4249510A1 (en) * | 2022-03-22 | 2023-09-27 | Stealth IO | Novel formats of anti-cd28/spd-1 fusion constructs |
| US20250282874A1 (en) | 2022-05-17 | 2025-09-11 | Suzhou Transcenta Therapeutics Co., Ltd. | Bifunctional protein, and preparation thereof and use thereof |
| EP4619435A1 (en) * | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US20100215640A1 (en) | 2003-04-24 | 2010-08-26 | The University Of North Carolina At Chapel Hill | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| US20100239578A1 (en) | 2007-10-11 | 2010-09-23 | University Health Network | Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| PL2995315T3 (pl) | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| EP3682896A1 (en) | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| JP7078533B2 (ja) | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| AU2016350701B2 (en) * | 2015-11-02 | 2021-08-19 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| SG11201808465UA (en) | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| RS66062B1 (sr) * | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| AU2019233577A1 (en) | 2018-03-13 | 2020-09-03 | Ose Immunotherapeutics | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies |
-
2018
- 2018-10-15 JP JP2020521372A patent/JP7395471B2/ja active Active
- 2018-10-15 US US16/754,285 patent/US11713356B2/en active Active
- 2018-10-15 WO PCT/EP2018/078082 patent/WO2019073080A1/en not_active Ceased
- 2018-10-15 CN CN201880079823.4A patent/CN111511766B/zh active Active
- 2018-10-15 EP EP18789355.7A patent/EP3694881A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536573A5 (https=) | ||
| CN109071664B (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| JP6896989B2 (ja) | 抗体結合ｌａｇ−３及びその使用 | |
| CN107474136B (zh) | 增强激动型抗体活性的抗体重链恒定区序列 | |
| JP7395471B2 (ja) | 改変抗ＳＩＲＰａ抗体及びその使用 | |
| AU2010299895B2 (en) | Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses | |
| CN102741282B (zh) | 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 | |
| JP2022177090A5 (https=) | ||
| KR102111171B1 (ko) | 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도 | |
| JP2022169504A (ja) | 新規な抗ＳＩＲＰａ抗体およびそれらの治療適用 | |
| JP2022169504A5 (https=) | ||
| JP2019530640A5 (https=) | ||
| JP2020529864A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2019528683A5 (https=) | ||
| HK1221409A1 (zh) | 抗ang2抗体和cd40激动剂的组合疗法 | |
| TW202039558A (zh) | 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途 | |
| CN117321087A (zh) | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 | |
| JP2019520034A5 (https=) | ||
| AU2009231482A1 (en) | Binding agents directed against IL-4 receptor for the treatment of tumors, inflammatory and immunological disorders | |
| CN106164094B (zh) | 双特异性抗原结合多肽 | |
| TW202108629A (zh) | 用於t細胞活化之抗體 | |
| US20250051444A1 (en) | Multi-specific t cell engagers comprising lrrc15 antigen-binding domain | |
| CN121263449A (zh) | Cd19/cd38多特异性抗体 | |
| US11685778B2 (en) | Anti-human LAG-3 monoclonal antibody and use thereof |